medigraphic.com
Órgano Oficial del Instituto Nacional de Pediatría

2014, Number 6

<< Back Next >>

Acta Pediatr Mex 2014; 35 (6)

Expanded newborn screening in the Health Services of the Mexican Navy

Trigo-Madrid M, Díaz-Gallardo J, Mar-Aldana R, Ruiz-Ochoa D, Moreno-Graciano C, Martínez-Cruz P, Herrera-Pérez LA, De la Torre-García O

Language: Spanish
References: 40
Page: 448-458
PDF size: 923.86 Kb.


ABSTRACT

In Mexico the birth prevalence of the metabolic diseases detected by expanded newborn screening is poorly known and there is little information about its performance indicators.
Objective. Describe the birth prevalence of the metabolic defects detected by the expanded newborn screening program implemented in the Mexican Navy (Secretaría de Marina Armada de México, SEMAR), and to make known some of its performance indicators.
Materials and Methods. A blood sample of 5 205 newborns from 18 Mexican states were taken. The age at blood sampling, the proportion of samples taken between the 3rd and the 5th days of life, and the time of results delivery were analyzed. The number and type of detected metabolic diseases, as well as the maternal age and body mass index, the type of birth, the gestational age and weight of the newborns were analized.
Results. The age at blood sampling was 4.7 days and 81.15 percent of the samples were obtained in optimal time. Two cases of congenital hypothyroidism (3.8/10 000 newborns), one of adrenal congenital hyperplasia (1.9/10 000 newborns) and five cases of deficiency of glucose- 6-phosphate dehydrogenase (9.6/10 000 newborns) were detected. The 85.6% of mothers had pregnancies at an optimal reproductive age (20-35 years), but overweight and obesity occurred in 44.7% of them.
Conclusions. In this analyzed population, the birth prevalence of metabolic defects was 15.37/10 000 newborns. The expanded newborn screening program allowed its identification and timely treatment, with the aim of preventing disability and death.


REFERENCES

  1. Velázquez A. El nuevo tamiz neonatal: una revolución en la pediatría preventiva. Bol Med Hosp Infant Mex 1998;55:313-315.

  2. AAP Newborn Screening Task Force. Serving the family from birth to the medical home-newborn screening: a blueprint for the future -a call for a national agenda on State newborn screening programs. Pediatrics 2000;106:389-422.

  3. Guthrie R, Susi A. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics 1963;32:338-43.

  4. Blau N, van Spronsen FJ, Levy HL. Phenylketonuria. Lancet 2010;376:1417-27.

  5. Dussault JH. The impact of systematic screening for congenital hypothyroidism. En: Farriaux J.P., Dhondt J.L. (eds) New Horizons in neonatal screening. Amsterdam: Elsevier Science, 1994; 123-129.

  6. Pollitt RJ. International perspectives on newborn screening. J Inherit Metab Dis 2006;29:390-6.

  7. Calonge N, Green NS, Rinaldo P, Lloyd-Puryear M, Dougherty D, Boyle C, et al. Advisory Committee on Heritable Disorders in Newborns and Children. Committee report: Method for evaluating conditions nominated for population- based screening of newborns and children. Genet Med 2010;12:153-9.

  8. Bennett MJ, Rinaldo P, Wilcken B, Pass KA, Watson MS, Wanders RJ. Newborn screening for metabolic disorders: how are we doing, and where are we going? Clin Chem 2012;58:324-31.

  9. Levy HL. Newborn screening: the genomic challenge. Mol Genet Genomic Med 2014;2:81-4.

  10. Norma Técnica 321 para la Prevención del Retraso Mental producido por Hipotiroidismo Congénito. México: Diario Oficial de la Federación, Órgano del Gobierno Constitucional de los Estados Unidos Mexicanos, Tomo CDXX; 1988. p. 89-90.

  11. Norma Oficial Mexicana NOM-007-SSA2-1993. Atención de la mujer durante el embarazo, parto y puerperio y recién nacido. Criterios y procedimientos para la prestación del servicio. México: Diario Oficial de la Federación, Órgano del Gobierno Constitucional de los Estados Unidos Mexicanos, Tomo CDXCVI; 1995. pp. 19-38.

  12. Vela-Amieva M, Belmont-Martínez L, Ibarra-González I, Fernández-Lainez C. Variabilidad interinstitucional del tamiz neonatal en México. Bol Med Hosp Infant Mex 2009;66:431-439.

  13. Norma Oficial Mexicana NOM-034-SSA2-2013. Para la prevención y control de los defectos al nacimiento. México: Diario Oficial de la Federación, Órgano del Gobierno Constitucional de los Estados Unidos Mexicanos, Tomo DCCXXIX, 24; 2014.

  14. CDC, US Department of Health and Human Services: using tandem mass spectrometry for metabolic disease screening among newborns. MMWR 2001;50, No. RR-3.

  15. Schulze A, Lindner M, Kohlmuller D, Olgemoller K, Mayatepek E, Hoffmann GF. Expanded newbornscreening for inborn errors of metabolism by electrospray ionizationtandem mass spectrometry: Results, outcome and implications. Pediatrics 2003;111:1399-1406.

  16. Beutler E. Glucose-6-phosphate dehydrogenase: new perspectives. Blood 1989;73:1397-1401.

  17. Mehta AB.Glucose-6-phosphate dehydrogenase deficiency. Postgrad Med J 1994;70:871-7.

  18. Elsas LJ, Langley S, Steele E, Evinger J, Fridovich-Keil JL, Brown A, et al.Galactosemia: a strategy to identify new biochemical phenotypes and molecular genotypes. Am J Hum Genet 1995;56:630-9.

  19. Levy HL, Hammersen G. Newborn screening for galactosemia and other galactose metabolic defects. J Pediatr 1978;92:871-877.

  20. Crossley JR, Elliot RP, Smith PA. Dried Blood-spot screening for cystic fibrosis in the newborn. Lancet 1979;1:472-474.

  21. Wolf B, Grier RE, McVoy JRS, Herard G S. Biotinidase deficiency: A novel vitamin recycling defect. J Inherited Metab Dis 1985;1(S8):53-58.

  22. Wolf B, Heard GS, Jefferson BS. Clinical findings in four children with biotinidase deficiency detected through newborn statewide neonatal screening program. N Engl J Med 1985;313:16-19.

  23. Burger HG, Pastel YC. Thyrotropin releasing hormone-TSH. Clin Endocrinol Metabol 1977;6:83-100.

  24. Berry J. The Interpretation of blood spot 17α-Hydroxyprogesterone level in term and preterm neonates. Ann Clin Biochem 1986;23:546-551.

  25. American Academy of Pediatrics Technical report: Congenital Adrenal Hyperplasie. Pedriatrics 2000;106:1511-1518.

  26. Langlois S, Ford JC, Chitayat D, Désilets VA, Farrell SA, Geraghty M, et al. Carrier screening for thalassemia and hemoglobinopathies in Canada. J Obstet Gynaecol Can 2008;10:950-71.

  27. Eastman JW, Wong R, Liao CL, Morales DR. Automated HPLC Screening of Newborns for sickle Cell Anemia and other Hemoglobinopathies. Clin Chem 1996;42:704-710.

  28. American College of Medical Genetics’ Newborn Screening Expert Group. Newborn screening: toward a uniform screening panel and system. Genet Med 2006;8(S1):1S-252S.

  29. Vela-Amieva-M, Gamboa-Cardiel-S, Pérez-M, Ortiz-J, Ortega V. Epidemiología del Hipotiroidismo Congénito. Salud Pública Mex 2004;46:141-147.

  30. Watchko JF, Kaplan M, Stark AR, Stevenson DK, Bhutani VK. Should we screen newborns for glucose-6-phosphate dehydrogenase deficiency in the United States? J Perinatol 2013;33:499-504.

  31. CDC. Ten great public health achievements. United States, 2001-2010. Morbidity and Mortality Weekly Report 2011;60:619-23.

  32. Giordano PC, Harteveld CL, Bakker E. Genetic epidemiology and preventive healthcare in multiethnic societies: the hemoglobinopathies. Int J Environ Res Public Health 2014;11:6136-46.

  33. Muthuswamy V. Ethical issues in genetic counselling with special reference to haemoglobinopathies. Indian J Med Res 2011;134:547-51.

  34. Vela-Amieva M, Ibarra-González I, Rodríguez-León GA, Chablé-Cupil G, Ávila-Guzmán C, Evaristo-López M y cols. Optimización del tiempo de diagnóstico del hipotiroidismo congénito en el Estado de Tabasco, México. Salud en Tabasco 2009;15:823-827.

  35. Blomberg M. Maternal obesity, mode of delivery, and neonatal outcome. Obstet Gynecol 2013;122:50-5.

  36. Mamun AA, Callaway LK, O'Callaghan MJ, Williams GM, Najman JM, Alati R, et al. Associations of maternal pre-pregnancy obesity and excess pregnancy weight gains with adverse pregnancy outcomes and length of hospital stay. BMC Pregnancy Childbirth. 2011;11:62.doi: 10.1186/1471-2393-11-62.

  37. Ovesen P, Rasmussen S, Kesmodel U. Effect of prepregnancy maternal overweight and obesity on pregnancy outcome. Obstet Gynecol 2011;118:305-312.

  38. Gaillard R, Steegers EA, Hofman A, Jaddoe VW. Associations of maternal obesity with blood pressure and the risks of gestational hypertensive disorders. The Generation R Study. J Hypertension 2011;29:937-944.

  39. Weiss JL, Malone FR, Emig D, et al. Obesity, obstetric complications and cesarean delivery rate: A population-based screening study. Am J Obstet Gynecol 2004;190:1091-1097.

  40. Stothard KJ, Tennant PW, Bell R, Rankin J. Maternal overweight and obesity and the risk of congenital anomalies: a systematic review and meta-analysis. JAMA 2009;301:636-50.




2020     |     www.medigraphic.com